secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-04-25T23:59:59+00:00
Accession:  0001193125-23-114750
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon updates pipeline and AP3 data; cash runway into Q4 2024
---------------------------------------------------------------

- Cash and marketable securities as of Dec 31, 2022 provide runway into at least Q4 2024.
- OncoSignature enriched ORR to 47% (NCI trial) and 58% (Lilly trial) vs 0% in non-responders.
- ACR-368 (CHK1/2) Phase 2 with registrational intent; new sensitive indications: endometrial and bladder cancer.
- WEE1 and PKMYT1 inhibitors expected to enter IND-enabling studies in 2023.
- Initial ACR-368 combination clinical readouts anticipated in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523114750/0001193125-23-114750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523114750/d482869d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-114750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer